Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 3/20 | 0.50 |
| ▸ | BACE1 | P56817 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.48 |
| ▸ | HTR2C | P28335 | 3/20 | 0.48 |
| ▸ | HTR2B | P41595 | 3/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | DRD4 | P21917 | 1/20 | 0.47 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5871813 | 0.93 | SIGMAR1 (0.53) | ACHEBACE1SIGMAR1HTR2CHTR2B | |
| SCHEMBL3652081 | 0.83 | HTR2A (0.60) | ACHEBACE1SIGMAR1HTR2CHTR2B | |
| SCHEMBL3652078 | 0.83 | HTR2A (0.60) | ACHEBACE1SIGMAR1HTR2CHTR2B | |
| SCHEMBL3818838 | 0.82 | HTR2C (0.54) | ACHEBACE1SIGMAR1HTR2CHTR2B | |
| SCHEMBL3818836 | 0.82 | HTR2C (0.54) | ACHEBACE1SIGMAR1HTR2CHTR2B | |
| SCHEMBL3823167 | 0.81 | SIGMAR1 (0.49) | ACHEBACE1SIGMAR1HTR2CHTR2B | |
| SCHEMBL5871500 | 0.79 | HTR1A (0.51) | SIGMAR1HTR2CHTR2BHTR1AMEN1 | |
| SCHEMBL5871015 | 0.77 | SIGMAR1 (0.55) | SIGMAR1HTR2CHTR2BHTR1A | |
| SCHEMBL11592645 | 0.77 | DRD2 (0.53) | ACHEBACE1SIGMAR1HTR2CHTR2B | |
| SCHEMBL3653205 | 0.77 | DRD2 (0.56) | ACHEBACE1SIGMAR1HTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7071201-B2 | Serotonin antagonism; muscle relaxant for myotonia; such as 1-(1-(2-(4-methoxyphenyl)ethyl)piperidin-4-yl)-7-methoxy-1,2,3,4 -tetrahydroquinoline | EISAI CO., LTD. (JP) | 2006-07-04 | — | — | US | disclosed |
| US-6579881-B2 | Indoles | EISAI CO., LTD. (JP) | 2003-06-17 | — | — | US | disclosed |
| US-6448243-B1 | SEROTONIN ANTAGONIST FOR TREATING, AMELIORATING AND PREVENTING SPASTIC PARALYSIS OR CENTRAL MUSCLE RELAXANTS FOR AMELIORATING MYOTONIA | EISAI CO., LTD. (JP) | 2002-09-10 | — | — | US | disclosed |
| US-20020086999-A1 | Certain quinoline derivatives | EISAI CO., LTD. | 2002-07-04 | — | — | US | disclosed |
| US-20020019531-A1 | Indoles | EISAI CO., LTD. | 2002-02-14 | — | — | US | disclosed |
| EP-0976732-A1 | 1,4-SUBSTITUTED CYCLIC AMINE DERIVATIVES | Eisai Co., Ltd. (JP) | 2000-02-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019531-A1 | Indoles | INMT, MUSK, MB | ACHE 459/4885BACE1 4259/4885SIGMAR1 1200/4885 |
| US-20020086999-A1 | Certain quinoline derivatives | CHRM1, CHRNA5, CHRNA4 | ACHE 182/4885BACE1 3717/4885SIGMAR1 523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.